A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
Clients presenting to the BCCDC STI clinic with genital warts will be randomized to either
400 mg zinc gluconate or placebo (200mg BID) for 8 weeks in addition to the standard of
care. Clinical assessment of warts and additional standard treatment will occur every 7-10
days for a maximum of 8 weeks. A telephone call will occur at week 20 to determine if any of
the warts have cleared or re-appeared. The appearance of new warts will also be noted. The
proportion of subjects who have complete clearance of genital warts at 8 weeks will be
compared between groups.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
complete clearance of genital warts
8 weeks
No
Richard Lester
Principal Investigator
University of British Columbia
Canada:None required
Oral Zinc RTC
NCT01468636
November 2011
Name | Location |
---|